PowerTOST robust [Power / Sample Size]

posted by d_labes  – Berlin, Germany, 2012-01-17 12:53 (5263 d 06:36 ago) – Posting: # 7956
Views: 10,793

Dear Ben,

❝ First, I want to say thanks for the great package PowerTOST!


Thanx for the flowers.

❝ I saw that you added some new features, in particular the df2 degrees of freedom. The latter brings me to my second point. In your excerpt (or the manual) you wrote "The df2 are also more appropriate if the planning of sample size is done based on CV’s originating from real mixed model analysis (via Proc MIXED in SAS or lme() in R)". Why is that? Is there a reference where this is mentioned (haven't seen it explicitly in Senn's "Cross-over Trials in Clinical Research")?


Sorry. No reference available. It's my personal observation looking at results of the FDA code for replicate studies (which uses Proc MIXED as you know).

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
107 visitors (0 registered, 107 guests [including 10 identified bots]).
Forum time: 20:29 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5